Common Impurities and What They Look Like

Recognise the classes without predicting the lot

Peptide-related impurities can arise during synthesis or later change. Some involve an altered sequence; others involve chemical modification or association of peptide molecules. Which pathways are relevant depends on the material and its history.

Bachem describes deletion and truncated sequences among synthesis-related by-products. EMA's synthetic-peptide guidance discusses oxidation, deamidation and higher-mass species, including covalent and noncovalent associations. These are analytical categories, not a prediction that any category occurs in a particular lot. [A2] [A8]

For the manufacturing context, see solid-phase peptide synthesis and impurity origins. The category name cannot replace a measured profile.

A missing residue and a shortened end are different descriptions

Use the invented sequence Ala–Gly–Ser–Leu as a reading example. Ala–Ser–Leu illustrates an internal Gly deletion. Gly–Ser–Leu illustrates loss of the N-terminal Ala. The example shows how to describe a sequence difference; it does not simulate a manufacturing result or establish how either species formed.

An actual synthesis-related fragment may also have a changed end group. Record the assigned structure rather than reducing every shorter signal to “deletion”. Evidence that two species have different masses is useful, but a complete assignment may need additional structural information.

A shoulder is a clue to investigate

A shoulder or adjacent peak can prompt investigation of separation and sample composition. It does not provide a chemical name. Examine the blank, repeatability, integration and method conditions before deciding what the feature represents. The chromatogram-reading guide explains the trace and peak table; HPLC analysis covers the area calculation.

The following is an invented evidence trail for a feature labelled X. It is an example of recording uncertainty, not a laboratory procedure or an actual investigation.

Keep “unidentified”, “tentatively assigned” and “confirmed under the stated method” distinct. ICH Q2(R2) explains that analytical selectivity can require evidence against interference and, where one method does not discriminate sufficiently, complementary methods. [A4]

Identification and quantity are separate results

After assigning a peak, ask how its amount was determined. A relative detector area is not automatically its percentage by mass. The response basis, calibration and any unresolved contributions belong with the number. A named impurity at an unsupported concentration is still an incomplete result. [A4]

Do not assume that a clean-looking main peak excludes every impurity class. A test designed around one measurement principle may need support from another. For higher-mass species, the report should distinguish the type of association and the method used rather than treating “dimer” and “aggregate” as interchangeable. [A8]

Use the profile for the decision it supports

Compare results only after checking the sample identity, method version, reporting limits and integration basis. If two reports use different methods, a different peak count alone does not demonstrate deterioration. The storage and stability guide explains the wider evidence needed to interpret change over time.

For a lot enquiry, request the actual profile, identified and unidentified entries, quantitation basis, and applicable acceptance criteria. The batch release and quarantine page provides the site's stated decision context; this explainer does not make a release decision for a lot.

Retain that evidence with your quality records. Identity, purity and assay helps separate the remaining questions. An impurity profile is useful because it records what was observed and established, including the assignments that remain unresolved.